Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants
1 clinical trials · Condition
◉ Watch Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants
| Record | Firm | Date |
|---|---|---|
| JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer (NCT06846437) | Shanghai JMT-Bio Inc. | 2025-02-18 |
Track Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants automatically
Every clearance here is in the API, with alerts when new ones post.